GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
Locked. A moderator closed replies on this one. It stays up because the content above the argument is worth keeping.
580
c/tirzepatide·posted 2 years ago by u/kaia_cabrera

am I the only one who found Zepbound harder than the injections

Lab The Quiet One ×3

am I the only one who found Zepbound harder than the injections, and I want the answer with the reasoning attached rather than just the conclusion.

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

Sceptical readings welcome. The confident ones are the ones I distrust.

607 up / 27 down96% upvoted10 commentsid 154ci431 May 2024

10 comments

10 in this archive, depth 3

best — the order this archive was captured in

u/alcohol_aversion49 points·2 years ago

Switching from semaglutide, since three people asked in this thread alone.

There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.

None of that is a recommendation. It is what the threads say, and the threads are not a clinic.

replysharereportpermalink
u/ignacio_vanhecke33 points·2 years ago

Are you comparing yourself with the trial mean or with the people who post the most?

replysharereportpermalink
u/teodor_szabo11 points·2 years ago

week 3 is early to draw any conclusion at all

replysharereportpermalink
u/santiago_villalobos34 points·2 years ago

Cosigning the four-week thing. It is a minimum interval, and treating it as a schedule to keep up with is how people end up miserable at 12.5.

replysharereportpermalink
u/swirl_dont_shakereconstitution26 points·2 years ago

pens and vials are the same molecule, the price is the difference

replysharereportpermalink
u/emil_barros21 points·2 years ago

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

replysharereportpermalink
[removed]15 points·2 years ago

[removed by moderator]

replysharereportpermalink
u/discount_math_dm33 points·2 years ago

Which week did the appetite change actually land for you?

replysharereportpermalink
u/mikkel_kimani24 points·2 years ago

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

replysharereportpermalink
u/forest_plot_fionastats14 points·2 years ago

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.